Sire Jean-Marie, Nabeth Pierre, Perrier-Gros-Claude Jean-David, Bahsoun Ibrahim, Siby Tidiane, Macondo Edgard Adam, Gaye-Diallo Aïssatou, Guyomard Stéphanie, Seck Abdoulaye, Breurec Sébastien, Garin Benoit
Laboratoire de Biologie Médicale, Institut Pasteur, Dakar, Senegal.
J Infect Dev Ctries. 2007 Dec 1;1(3):263-8.
Data regarding the evolution of antimicrobial resistance are needed to suggest appropriate empirical treatment of urinary tract infections (UTI) in developing countries. To assess the antimicrobial susceptibility of Escherichia coli, the predominant pathogen in community-acquired UTI, a prospective multicenter study was carried out in Dakar, Senegal.
From February 2004 to October 2006, 1010 non-duplicate E. coli strains were collected from four centres. Antimicrobial susceptibility testing was performed using disk diffusion method according to the recommendations of the CA-SFM (2004).
Most of the isolates were resistant to amoxicillin (73.1%), amoxicillin-clavulanic acid (67.5%), cephalothin (55.8%), and trimethoprim/sulfamethoxazole (68.1%). Extended spectrum beta-lactamase was detected in 38 strains. The overall resistance rates to nalidixic acid, norfloxacin and ciprofloxacin were 23.9%, 16.4% and 15.5%, respectively. Most of the strains were susceptible to gentamicin, nitrofurantoin and fosfomycin (respective susceptibility rates, 93.8%, 89.9%, and 99.3%). During this period, a significant decrease in sensitivity was observed for cephalothin, fluoroquinolones and trimethoprim/sulfamethoxazole (p<0.001).
These data suggest that trimethoprim/sulfamethoxazole may no longer be used as empirical treatment for community-acquired UTI in Dakar. In order to preserve the activity of fluoroquinolones for future years, alternatives such as fosfomycin or nitrofurantoin should be considered.
在发展中国家,需要有关抗菌药物耐药性演变的数据来指导对尿路感染(UTI)进行适当的经验性治疗。为评估社区获得性UTI的主要病原菌大肠杆菌的抗菌药物敏感性,在塞内加尔达喀尔开展了一项前瞻性多中心研究。
2004年2月至2006年10月,从四个中心收集了1010株非重复的大肠杆菌菌株。根据CA-SFM(2004年)的建议,采用纸片扩散法进行抗菌药物敏感性试验。
大多数分离株对阿莫西林(73.1%)、阿莫西林/克拉维酸(67.5%)、头孢噻吩(55.8%)和甲氧苄啶/磺胺甲恶唑(68.1%)耐药。在38株菌株中检测到超广谱β-内酰胺酶。对萘啶酸、诺氟沙星和环丙沙星的总体耐药率分别为23.9%、16.4%和15.5%。大多数菌株对庆大霉素、呋喃妥因和磷霉素敏感(各自的敏感率分别为93.8%、89.9%和99.3%)。在此期间,观察到头孢噻吩、氟喹诺酮类和甲氧苄啶/磺胺甲恶唑的敏感性显著下降(p<0.001)。
这些数据表明,在达喀尔,甲氧苄啶/磺胺甲恶唑可能不再用作社区获得性UTI的经验性治疗药物。为了在未来几年保持氟喹诺酮类药物的活性,应考虑使用磷霉素或呋喃妥因等替代药物。